A detailed history of Nuveen Asset Management, LLC transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 108,750 shares of FDMT stock, worth $2.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
108,750
Previous 108,750 -0.0%
Holding current value
$2.27 Million
Previous $2.2 Million 57.24%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$9.76 - $21.25 $13,498 - $29,388
1,383 Added 1.29%
108,750 $2.2 Million
Q3 2023

Nov 14, 2023

BUY
$12.64 - $19.76 $126,994 - $198,528
10,047 Added 10.32%
107,367 $1.37 Million
Q2 2023

Aug 14, 2023

SELL
$15.16 - $23.26 $899,154 - $1.38 Million
-59,311 Reduced 37.87%
97,320 $1.76 Million
Q1 2023

May 15, 2023

BUY
$15.45 - $23.19 $425,400 - $638,513
27,534 Added 21.33%
156,631 $2.69 Million
Q4 2022

Feb 14, 2023

SELL
$6.85 - $25.46 $117,162 - $435,467
-17,104 Reduced 11.7%
129,097 $2.87 Million
Q3 2022

Nov 14, 2022

SELL
$6.96 - $11.48 $2,185 - $3,604
-314 Reduced 0.21%
146,201 $1.18 Million
Q2 2022

Aug 15, 2022

BUY
$5.68 - $15.99 $299,120 - $842,065
52,662 Added 56.11%
146,515 $1.02 Million
Q1 2022

May 16, 2022

SELL
$13.16 - $22.64 $45,704 - $78,628
-3,473 Reduced 3.57%
93,853 $1.47 Million
Q4 2021

Feb 14, 2022

BUY
$19.56 - $32.94 $125,653 - $211,606
6,424 Added 7.07%
97,326 $1.93 Million
Q3 2021

Nov 12, 2021

BUY
$22.73 - $36.04 $1.45 Million - $2.31 Million
63,980 Added 237.65%
90,902 $3.16 Million
Q2 2021

Aug 16, 2021

BUY
$22.2 - $42.29 $204,040 - $388,687
9,191 Added 51.84%
26,922 $648,000
Q1 2021

May 17, 2021

BUY
$35.94 - $52.67 $637,252 - $933,891
17,731 New
17,731 $769,000

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $675M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.